We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Medical

Carocell Bio

Status: Unknown

Sep 28th 2020 - May 28th 2021

Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.

read more read less

Carocell Bio Rating Review

Pitch rating powered by CROWDRATING

Rated on 13/10/2020

Pitch Rated

45%

Insufficient Data

Management

77%

Product

58%

Investment

UNRATED*

* Section unrated owing to insufficient or incomplete information available at the time of rating.

Log in to view amount pledged

    Log in to view target

    £4,058,252
    pre-money valuation

    9.09%
    equity available

    Withheld
    investors

    Withheld
    pledge per investor

    10469714
    company number

    Active
    company status

    08/11/2016
    incorporated 8 years

    £0.04
    share price

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own
    50-64%
    Room for improvement
    65-79%
    Worth considering
    80%+
    Gold rating, our highest rating

RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.

Login to view the full report

Management 77%

Skills 73%
Carocell Bio’s Management team is led by the Founder/CEO, who has expertise in early-stage development and taking medicines from ideation to the market. He is skilled in clinical development, drug discovery, clinical research, medical education, drug development, pharmacology, and regulatory submissions. The Chairman is an expert in clinical development, biotechnology, cell culture, new business development, strategic leadership, technology transfer, and toxicology. The Marketing Director is well versed in brand development, marketing management, business administration, SEO copywriting, strategic planning, production management, online advertising, and marketing communications. It was noted that they have not, as yet, appointed a dedicated Finance Head and CEO is also taking up the responsibilities of Product Developer in the team.

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


Log in to view amount pledged

    Log in to view target

    £4,058,252
    pre-money valuation

    9.09%
    equity available

    Withheld
    investors

    Withheld
    pledge per investor

    10469714
    company number

    Active
    company status

    08/11/2016
    incorporated 8 years

    £0.04
    share price

  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph